Majority of newborn babies with spinal muscular atrophy (SMA) treated with Evrysdi (risdiplam) are able to sit independently after 1 year of treatment – Roche
Roche presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi (risdiplam) in babies with pre-symptomatic SMA (n=26), aged… read more.
